Ruowen Ge

Title: Ruowen Ge: Innovator in Anti-Angiogenic Peptides

Introduction

Ruowen Ge is a prominent inventor based in Singapore, SG. He has made significant contributions to the field of biotechnology, particularly in the development of small peptides with anti-angiogenic properties. With a total of 2 patents, his work focuses on addressing critical health issues related to tumor growth and metastasis.

Latest Patents

Ruowen Ge's latest patents include innovative peptides that exhibit potent anti-angiogenic activity. The first patent describes small peptides that possess both anti-angiogenic and endothelial cell proliferation inhibition activity. These peptides can be formulated into pharmaceutical compositions aimed at preventing or treating undesired angiogenesis, which is crucial for inhibiting tumor metastasis and primary tumor growth. The second patent further emphasizes the anti-angiogenic properties of these peptides, reinforcing their potential in therapeutic applications.

Career Highlights

Ruowen Ge is affiliated with the National University of Singapore, where he conducts research and development in the field of peptide technology. His academic and professional journey has been marked by a commitment to advancing medical science through innovative solutions.

Collaborations

Ruowen Ge collaborates with R Manjunatha Kini, a fellow researcher, to enhance the scope and impact of their work in the field of anti-angiogenic therapies.

Conclusion

Ruowen Ge's contributions to the development of anti-angiogenic peptides represent a significant advancement in the fight against cancer. His innovative work continues to pave the way for new therapeutic options in the medical field.